Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NYMX

Nymox Pharmaceutical (NYMX) Stock Price, News & Analysis

Nymox Pharmaceutical logo

About Nymox Pharmaceutical Stock (NASDAQ:NYMX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.19
$0.47
52-Week Range
N/A
Volume
932,700 shs
Average Volume
94,622 shs
Market Capitalization
$18.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive NYMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

NYMX Stock News Headlines

Nymox Announces Filing of Annual Report
Nymox Annual Report
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
Nymox December 27 Message to Shareholders
See More Headlines

NYMX Stock Analysis - Frequently Asked Questions

Nymox Pharmaceutical Co. (NASDAQ:NYMX) posted its quarterly earnings results on Friday, November, 14th. The biopharmaceutical company reported ($0.02) EPS for the quarter. The biopharmaceutical company earned $0.08 million during the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Idera Pharmaceuticals (IDRA), MEI Pharma (MEIP), Biocept (BIOC), TherapeuticsMD (TXMD) and CTI BioPharma (CTIC).

Company Calendar

Last Earnings
11/14/2014
Today
8/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Diagnostic substances
Sub-Industry
N/A
Current Symbol
NASDAQ:NYMX
CIK
1018735
Employees
3
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$6.58 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-1,589.50%
Return on Assets
-117.25%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.19
Quick Ratio
0.19

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.01) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
90,510,000
Free Float
41,637,000
Market Cap
$18.10 million
Optionable
Optionable
Beta
0.64
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:NYMX) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners